Gyre Therapeutics (GYRE) Cash & Equivalents (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Cash & Equivalents data on file, last reported at $37.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 917.36% year-over-year to $37.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.5 million (up 917.36% YoY) and the FY2025 annual result came in at $24.9 million, up 110.81% from the prior year.
• Cash & Equivalents rose to $37.5 million in Q1 2026 per GYRE's latest filing, from $24.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $75.4 million in Q2 2022 and bottomed at $2.2 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $23.1 million (2022), against an average of $23.9 million.
• The widest annual swing landed in 2023, when Cash & Equivalents slumped 90.48%; it then jumped 917.36% in 2026.
• Tracing GYRE's Cash & Equivalents over 5 years: stood at $25.2 million in 2022, then jumped by 33.1% to $33.5 million in 2023, then sank by 64.79% to $11.8 million in 2024, then soared by 110.81% to $24.9 million in 2025, then soared by 50.75% to $37.5 million in 2026.
• Per Business Quant, the three latest GYRE Cash & Equivalents figures stand at $37.5 million (Q1 2026), $24.9 million (Q4 2025), and $40.4 million (Q3 2025).

Peer Comparison